A detailed history of Voya Investment Management LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 169,711 shares of RYTM stock, worth $6.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
169,711
Previous 64,991 161.13%
Holding current value
$6.97 Million
Previous $2.99 Million 146.17%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $4.1 Million - $5.49 Million
104,720 Added 161.13%
169,711 $7.35 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $412,142 - $956,463
-19,268 Reduced 22.87%
64,991 $2.99 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $3,494 - $6,143
221 Added 0.26%
84,259 $1.93 Million
Q2 2023

Aug 14, 2023

BUY
$16.32 - $21.15 $333,629 - $432,369
20,443 Added 32.15%
84,038 $1.39 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $273,458 - $1.96 Million
63,595 New
63,595 $1.56 Million
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $53,713 - $210,896
-17,216 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.62 - $13.9 $370 - $597
-43 Reduced 0.25%
17,216 $172,000
Q2 2021

Aug 16, 2021

BUY
$18.52 - $22.55 $22,742 - $27,691
1,228 Added 7.66%
17,259 $338,000
Q1 2021

May 17, 2021

BUY
$20.25 - $39.49 $25,616 - $49,954
1,265 Added 8.57%
16,031 $341,000
Q4 2020

Feb 16, 2021

BUY
$21.17 - $32.61 $55,888 - $86,090
2,640 Added 21.77%
14,766 $439,000
Q2 2020

Aug 14, 2020

SELL
$14.41 - $25.35 $38,474 - $67,684
-2,670 Reduced 18.05%
12,126 $270,000
Q1 2020

May 15, 2020

BUY
$13.16 - $22.9 $11,133 - $19,373
846 Added 6.06%
14,796 $225,000
Q4 2019

Feb 14, 2020

BUY
$19.53 - $25.5 $272,443 - $355,725
13,950 New
13,950 $320,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.29B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.